- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04428086
A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.
Open-Label, Fixed-Sequence Study in Solid Tumor Subjects to Investigate the Pharmacokinetic Interaction Between Apatinib and Transporter Substrates Rosuvastatin and Metformin.
The primary objective of the study was to assess investigate the pharmacokinetic effects of Apatinib on Rosuvastatin or Metformin.
The secondary objective of the study was to assess the safety of Apatinib alone or Rosuvastatin/Metformin alone or concomitant medication.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050035
- The Fourth Hospital of Hebei Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must meet all of the following criteria to enter the study:
- Age: 18-70 years old (Include both values);
- Patients with histopathologically or cytologically confirmed advanced solid tumor(except primary gastrointestinal tumors or metastatic gastrointestinal tumors and primary hepatocellular tumors) , not necessary to have measurable lesions;
- The standard systemic treatment plan for tumors is ineffective, or intolerable, or there is no recurrence and metastasis after adjuvant chemotherapy and radiotherapy after surgery;
- ECOG PS score: 0-1;
- Expected survival ≥ 3 months;
- Adverse reactions caused by the subject receiving other treatments have recovered (recovered to ≤ grade 1 according to NCI-CTCAE 5.0, except for hair loss), more than 4 weeks after receiving radiotherapy or surgery or receiving other cytotoxic drugs or cell growth inhibitor.
Major organs must function normally, meeting the following criteria:
I. Haematology (no blood transfusion or blood products within the last 14 days, not corrected with G-CSF or other hematopoietic colony-stimulating factors):
- HB≥100 g/L;
- ANC≥1.5×109/L;
- PLT≥90×109/L;
II. Blood biochemistry:
- TBIL≤ 1.25×ULN;
- ALT and AST≤2.5×ULN;
- ALP≤2.5×ULN;
- Serum Cr ≤ 1.5 × ULN or endogenous CrCl ≥ 60 mL/min (Cockcroft-Gault formula);
- Albumin > 30 g/L;
III. Urine protein inspection:
a. Urinary routines suggest that urine protein <++. If urinary protein ≥ ++, the quantification of urinary protein in 24 hours should be ≤1.5 g;
- Agree to abstinence or take effective contraception during the study and for at least 8 weeks after the last study drug administration
- Sign the ICF voluntarily, have good compliance, corporate with follow-up visits, and follow the study requirements.
Exclusion Criteria:
Subjects meeting any one of the followings will be excluded in this study:
- Patients with gastrointestinal diseases that affect the use or absorption of drugs, such as gastric cancer or intestinal cancer, unable to swallow, chronic diarrhea, intestinal obstruction, large stomach or total gastrectomy, or within 6 months before the first medication Patients with abdominal fistula, gastrointestinal perforation or abdominal abscess;
- Active (without medical control) brain metastases, cancerous meningitis, spinal cord compression patients, or imaging CT or MRI examination at screening to find diseases of the brain or pia mater
- Presence of clinically symptomatic third space fluid (e.g. large pleural fluid or ascites) that cannot be controlled by drainage or other methods;
- Patients with hypertension, or patients with a history of hypertension
- Patients with NYHA Class III-IV cardiac insufficiency or left ventricular ejection fraction (LVEF) < 50% by echocardiography; uncontrolled arrhythmias (QTc interval ≥ 450 ms in males and ≥ 470 ms in females);
- During the study period, patients should be used drugs that may lead to prolonged QTc interval (such as antiarrhythmic drugs, quinidine, disopyramide, procainamide, sotalol, amiodarone, etc.)
- Patients with abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN + 4 s or APTT > 1.5 ULN)
- Patients with clinically significant bleeding or clear bleeding tendency within 3 months prior to the first dose, such as coughing up blood, hemoptysis, GI bleeding, hemorrhagic gastric ulcer, or baseline fecal occult blood (FOB) ++ and above. Gastroscopy is required for patients with FOB (+) and no surgical resection of primary gastric tumor. In case of ulcerative gastric cancer, patients are not enrolled due to a risk of acute gastrointestinal hemorrhage;
- Events of arterial/venous thrombosis within 6 months prior to the first dose, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, brain infarction), deep vein thrombosis, and pulmonary embolism;
- Known hereditary or acquired hemorrhage and thrombophilia (such as hemophilia, coagulopathy, thrombocytopenia, hypersplenism, etc.);
- Patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or similar drugs;
- Have undergone major surgery or with severe traumatic injury, fracture, or ulcer within 4 weeks prior to the first dose; There is no previous wound healing.
- Use of study drugs in other clinical trials within 4 weeks prior to the first dose;
- Drugs that is CYP3A inhibitor, or the transporter BCRP or MATE1 inhibitor, or drugs that affect gastric acid secretion, or Chinese herbal medicines within 2 weeks before the first dose; use the drug that is metabolic enzyme CYP3A inducer within 4 weeks before the first dose
- Infectious disease screening (hepatitis B virus surface antigen, hepatitis C virus antibody, Treponema pallidum antibody and human immunodeficiency virus antibody) positive
- History of immunodeficiency, with acquired, congenital immunodeficiency disease, or history of organ transplantation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Assess PK effects of Apatinib on Rosuvastatin
Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 7 and Apatinib at a dose of 250 mg once daily from Day 4 until Day 9.
|
Apatinib will be administered at a dose of 250 mg once daily from Day 4 to Day 9.
Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 7.
|
Experimental: Assess PK effects of Apatinib on Metformin
Participant will be administered a single oral dose of metformin 500 milligram (mg) on Day 1 and Day 6 and Apatinib at a dose of 250 mg once daily from Day 3 until Day 7.
|
Apatinib will be administered at a dose of 250 mg once daily from Day 3 to Day 7.
Metformin will be administered as a single oral 500 mg on Day 1 and Day 6.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Plasma Concentration (Cmax)
Time Frame: Up to Day 10
|
The Cmax is the maximum observed concentration
|
Up to Day 10
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])
Time Frame: Up to Day 10
|
The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.
|
Up to Day 10
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])
Time Frame: Up to Day 10
|
The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time
|
Up to Day 10
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: through study completion, an average of 35 or 37 days in two groups.
|
An adverse event is any untoward medical occurrence in a patient or clinical study participant criteria
|
through study completion, an average of 35 or 37 days in two groups.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Antineoplastic Agents
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Protein Kinase Inhibitors
- Rosuvastatin Calcium
- Metformin
- Apatinib
Other Study ID Numbers
- HR-APTN-I-010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor, Adult
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Institut CurieRecruitingChemotherapy Effect | Solid Tumor, Adult | Solid Tumor, ChildhoodFrance
-
New York Stem Cell Foundation Research InstituteStevens Institute of TechnologyRecruiting
-
JemincareNot yet recruiting
Clinical Trials on Apatinib in arm1
-
Sorlandet Hospital HFOslo University Hospital; Helse Stavanger HF; Haukeland University Hospital; St... and other collaboratorsCompleted
-
Assistance Publique - Hôpitaux de ParisUnknownChildren | Crigler Najjar SyndromeFrance
-
Assistance Publique - Hôpitaux de ParisRecruitingCoronary Artery Disease | Percutaneous Coronary Intervention | Coronary Artery Bypass GraftingFrance
-
Shen LinUnknownColorectal Cancer | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancer | Targeted Therapy | HER2China
-
Shanghai Chest HospitalUnknownUnresectable Stage III Non-small-cell Lung CancerChina
-
University of OregonCompletedSubstance-Related Disorders | Smoking | Alcohol Drinking | Prescription Drug Abuse | Oral Intake ReducedUnited States
-
Elevar TherapeuticsCompletedAdenoid Cystic CarcinomaUnited States, Korea, Republic of
-
Shanghai Jiao Tong University Affiliated Sixth...UnknownSoft Tissue Sarcoma
-
Tianjin Medical University Cancer Institute and...Unknown